Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Agora Inc (API) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Agora Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Agora Inc trades at $4.2 (market cap $355.95M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 112.1× Agora Inc's market cap, and Agora Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | API | |
|---|---|---|
Market Cap | $39.89B | $355.95M |
Sector | Health | Technology |
52-Week High | $491.22 | $5.26 |
52-Week Low | $278.09 | $3.24 |
Enterprise Value | $38.15B | $108.94M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Agora, Inc. (API) trades at $4.22, down 2.54% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q1 2026 revenue above guidance and its sixth consecutive quarter of GAAP profitability, with net income of $9.53 million in 2025. Recent news highlights management share purchases and a partnership with thymia for real-time health intelligence.
Outlook remains positive with analyst consensus at 60% buy ratings, supported by strong cash flow growth and a low P/B of 0.64. Key risks include competitive pressures in conversational AI and potential volatility from high short interest growth of 30.3% as of March 31, 2026 (Defense World).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Agora Inc
Agora Inc provides real-time communication solutions. The company offers real-time video calling, voice calling, live audio and video streaming, recording, and real-time messaging. It serves the gaming, retail, and education industries. The company operates in the People's Republic of China and the United States of America and the majority of its revenue is derived from the People's Republic of China.
Read more on API →
